Regeneron and Sanofi Strike $8 Billion Extension Deal, Resolving Litigation While Targeting Twice-a-Year Dosing to Defend Dupixent's Successor Franchise
Special call held October 1, 2026 to announce expanded Type 2 inflammation collaboration
Regeneron Pharmaceuticals and Sanofi used a special conference call on October 1, 2026 to unveil an expanded partnership that extends their nearly two-decade Dupixent alliance into a new generation of long-acting antibodies, while simultaneously resolving an underlying dispute between the two companies. The restructured deal commits Regeneron to contribute four fully human antibodies targeting the IL4 and IL13 pathways, with Sanofi paying $1 billion upfront and up to $7 billion in additional milestones, for a total deal value of $8 billion. Profits and R&D costs on the new medicines will be split 50-50, a construct both companies repeatedly described as a "partnership of equals."
Deal Terms Quietly Resolve Prior Litigation
Perhaps the most notable disclosure came almost in passing: the new agreement resolves ongoing litigation between Regeneron and Sanofi tied to the original Dupixent alliance terms, a dispute neither company had previously detailed in much depth on public calls. Sanofi CEO Belen Garijo Lopez characterized the restructuring as bringing "a stronger and more durable framework for our alliance, clearer governance, greater transparency and the resolution of the litigation between our companies." Governance has been simplified along functional lines: Regeneron now holds final decision-making authority on development, while Sanofi retains final commercial decision rights including pricing and access, with Regeneron gaining expanded involvement in payer engagements. CEO Leonard Schleifer was candid when asked by BMO Capital Markets' Evan Seigerman why Regeneron, sitting on a large cash balance, needed to accept a fresh upfront payment at all, replying that the structure "was just a matter of creating a fair relationship, and that's what the payment was intended to be part of," a comment that reads as confirmation the prior arrangement had grown contentious.
Four New Antibodies Built for Dosing Convenience, Not New Biology
Regeneron is contributing a lead IL13 ligand-blocking antibody already in clinic for atopic dermatitis, alongside three preclinical assets: an IL4/IL13 bispecific, an IL4 receptor-alpha antibody, and a standalone IL4 antibody. All four were built on Regeneron's VELOCIMMUNE platform, the same technology that produced Dupixent, and all target extended dosing intervals rather than new mechanisms. Chief Scientific Officer George Yancopoulos was explicit that the science does not support chasing alternative pathways: "the overwhelming data demonstrates the critical central roles for IL4 and IL13 in all of these Type 2 diseases... there are not other pathways that are strongly driving or can supplement the remarkable efficacy and safety profiles that we've seen with Dupixent." The lead IL13 candidate is targeting a dosing interval of at least every three to six months, versus Dupixent's current every-two-week regimen, with registrational studies expected to begin in late 2027 or early 2028. Sanofi separately retains an option, exercisable at Regeneron's discretion, to bring lunsekimig, its IL13/TSLP Nanobody currently in Phase III for COPD, into the alliance pending that readout.
Yancopoulos Takes Direct Aim at Competing IL13 Programs
The most pointed commentary of the call came in response to a question from Jefferies' Akash Tewari about rival IL13 and trispecific data presented that same morning at the EADV conference. Yancopoulos dismissed competing next-generation IL13 antibodies as derivative engineering rather than genuine innovation, stating the newest entrants are "essentially just reengineered, more highly engineered, which is more likely to cause problems as opposed to advantages than already existing IL13 antibodies," adding that one such molecule is "just a rehumanized version of lebrikizumab or Ebglyss, which actually already failed in asthma and other respiratory indications." He argued Regeneron's fully human, non-engineered approach avoids the anti-drug antibody and manufacturing issues that plague heavily engineered competitors, positioning the new IL13 asset as potentially best-in-class on biopharmaceutical grounds rather than mechanism novelty. When Wolfe Research's Alexandria Hammond pressed on whether Regeneron would run head-to-head superiority trials against its own Dupixent franchise, given a competitor is now doing so, Schleifer declined to commit, saying only that "George and the team will be unfolding the strategy fairly quickly."
Dupixent Exclusivity Timeline and the $20 Billion Atopic Dermatitis Opportunity
Dupixent itself continues to scale, with second-quarter 2026 global net sales of EUR 5.2 billion putting the drug on an annualized run-rate above EUR 20 billion across nine approved indications and more than 1.5 million patients worldwide. Management framed the atopic dermatitis market as still early in its development curve, with only about 20% of eligible U.S. patients currently on advanced therapy and the U.S. market projected to reach approximately $20 billion by 2032, with advanced therapy penetration exceeding 50% by 2040. On the critical question of patent exclusivity, Intron Health's Naresh Chouhan pushed Sanofi CFO François-Xavier Roger on whether the deal economics only make sense if Dupixent avoids biosimilar competition when the new antibodies launch. Roger confirmed the U.S. loss of exclusivity date remains March 2031 but said the companies are "actively working to extend the LOE of Dupixent a few years behind the original LOE," while declining to offer certainty. Garijo Lopez added that this agreement is "a deliberate first step in the transformation of Sanofi" and that more details on preparing for the 2031-2032 loss of exclusivity window would follow.
Milestone Cadence and Near-Term Catalysts
On deal mechanics, Schleifer indicated the first $1 billion milestone payment under the new agreement is tied to the start of Phase III trials for the lead IL13 asset, with the remainder of the $7 billion in contingent payments spread across subsequent development, regulatory, and commercial achievements. Sanofi's Manuela Buxo and Paulo Fontoura separately addressed the lunsekimig optionality, noting the COPD Phase II/III data will drive the joint decision on whether that asset enters the alliance, with no indication Regeneron plans to absorb it ahead of that readout. Sanofi also clarified that its independent STAT6 program and other immunology assets outside the alliance remain active and unaffected by the new agreement, underscoring that both companies still view immunology as a battleground extending beyond the Regeneron partnership.